Silence Therapeutics (NASDAQ:SLN) Stock Falls 6.4% – Should You Sell?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN)’s stock price was down 6.4% during mid-day trading on Tuesday. The stock traded as low as $9.07 and last traded at $9.0330. 497,046 shares traded hands during mid-day trading, a decline of 18% from the average session volume of 607,693 shares. The stock had previously closed at $9.65.

Analyst Ratings Changes

A number of research analysts have recently commented on SLN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. Morgan Stanley upped their price objective on shares of Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, June 17th. Finally, Cantor Fitzgerald initiated coverage on shares of Silence Therapeutics in a research report on Wednesday, June 24th. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.50.

Silence Therapeutics Stock Down 8.5%

The firm has a market cap of $531.35 million, a price-to-earnings ratio of -6.90 and a beta of 1.45. The stock’s 50 day moving average is $12.57 and its 200 day moving average is $9.51.

Silence Therapeutics (NASDAQ:SLN) last released its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. Analysts anticipate that Silence Therapeutics PLC Sponsored ADR will post -1.03 earnings per share for the current fiscal year.

Institutional Trading of Silence Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SLN. Squarepoint Ops LLC grew its holdings in Silence Therapeutics by 29.6% during the second quarter. Squarepoint Ops LLC now owns 115,918 shares of the company’s stock worth $1,273,000 after acquiring an additional 26,449 shares during the period. AXQ Capital LP bought a new stake in Silence Therapeutics in the second quarter worth about $138,000. 5AM Venture Management LLC acquired a new stake in Silence Therapeutics in the 2nd quarter valued at about $5,228,676. GAMMA Investing LLC lifted its holdings in Silence Therapeutics by 18.1% in the 2nd quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock valued at $121,000 after acquiring an additional 1,698 shares during the last quarter. Finally, Seven Fleet Capital Management LP lifted its holdings in Silence Therapeutics by 6.2% in the 1st quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company’s stock valued at $826,000 after acquiring an additional 9,159 shares during the last quarter. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-causing proteins. The company’s approach is designed to act at the genetic level by targeting specific messenger RNA molecules before they are translated into proteins.

Silence’s research is supported by its proprietary mRNAi GOLD platform, which is intended to enable the development and delivery of small interfering RNA (siRNA) medicines.